Scilex (SCLX) Stock: Buy, Sell, or Hold?
SCLX - Scilex Holding Company Common Stock
$4.49
-0.40 (-8.18%)
▼
5d:
-12.98%
30d:
-19.39%
90d:
-42.44%
WAIT
LOW Confidence
Analysis Updated: Sep 28, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When SCLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SCLX is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SCLX is down 13.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.47
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.64
3.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SCLX is currently trading at $4.49, which is considered oversold relative to its 30-day fair value range of $4.98 to $5.54. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.2) compared to its historical average (7.3). Remarkably, the market is currently pricing in an annual earnings decline of 5.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SCLX is in a downtrend. The price is currently testing key support at $4.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $490.00 (+10813.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SCLX is in a downtrend. The price is currently testing key support at $4.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock scores a mixed 55/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $490.00 (+10813.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.98 -
$5.54
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.2%)
- BULLISH: Trading 10813.2% below Wall St target ($490.00)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.98 -
$5.54
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.45
Resistance Level
$5.60
Current Trend
Downtrend
Technical data as of
Sep 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.15
Wall Street Target
$490.00
(+10813.2%)
Revenue Growth (YoY)
-22.8%
Valuation Discount vs History
-5.4% cheaper
PE vs Historical
6.2 vs 7.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.4%
(market-implied from PE analysis)
1-Year Target
$4.25
(-5%)
2-Year Target
$4.02
(-11%)
3-Year Target
$3.80
(-15%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$4.51
(+1%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.2 to 7.3
Stabilization Target:
$5.33
(+18.7%)
PE Expansion Potential:
+18.7%
Share & Embed Analysis
Last updated: September 29, 2026 9:19 AM ET
Data refreshes hourly during market hours. Next update: 10:19 AM
Data refreshes hourly during market hours. Next update: 10:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1325 | 47 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$389 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$159 | 35 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$279 | 49 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 47 HOLD |
